The earnings call reflects a strong financial performance with significant revenue growth across key products, particularly FIRDAPSE and AGAMREE. However, challenges remain with the decline in FYCOMPA revenue due to generic competition and increased operational expenses. The strategic initiatives and strengthened leadership team position Catalyst for sustained growth, though uncertainties in patent litigation may impact future performance.

Company Guidance

During the Catalyst Pharmaceuticals Q2 2025 earnings call, the company reported a record-setting quarter with total revenue of $146.6 million, marking a 19.4% increase year-over-year. Their flagship product, FIRDAPSE, generated $84.8 million in net product revenue, growing 9.7% from Q2 2024, while AGAMREE saw a remarkable 213% year-over-year increase, reaching $27.4 million. FYCOMPA generated $34.3 million in revenue despite a 6% year-over-year decline due to anticipated generic competition. Catalyst maintained a strong cash position of $652.8 million and reaffirmed their 2025 revenue guidance of $545 million to $565 million. The company also highlighted a strategic expansion of FIRDAPSE into oncology and educational efforts to diagnose undiagnosed cancer-associated LEMS patients, potentially expanding their market. They are confident in sustaining growth, backed by a significant presence in Duchenne Muscular Dystrophy treatment and strategic initiatives to offset FYCOMPA's loss of exclusivity.

Record-Setting Revenue Growth

Catalyst Pharmaceuticals reported total revenue of $146.6 million for Q2 2025, a 19.4% year-over-year increase. The first half of 2025 saw a 30.2% increase in total revenue, reaching $288 million.

Strong Performance of FIRDAPSE

FIRDAPSE generated net product revenue of $84.8 million in Q2 2025, a $7.5 million increase compared to Q2 2024. The first half of 2025 saw a 16.9% increase in net product revenue over the same period in 2024.

AGAMREE's Exceptional Growth

AGAMREE achieved $27.4 million in Q2 2025 net product revenue, a 213% increase year-over-year. The first half of 2025 saw a 398% increase in net revenues.

Strong Cash Position

The company ended Q2 2025 with a cash position of $652.8 million, showcasing its ability to invest strategically for long-term growth.

New Leadership and Strategic Initiatives

Dr. Will Andrews joined as Chief Medical Officer, and Dr. Dan Curran was added to the Board of Directors, strengthening the leadership team.

Catalyst Pharma (CPRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CPRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.33 / -	0.35	―	―	―
Aug 06, 2025	2025 (Q2)	0.39 / 0.41	0.33	24.24% (+0.08)	―
May 07, 2025	2025 (Q1)	0.34 / 0.45	0.19	136.84% (+0.26)	―
Feb 26, 2025	2024 (Q4)	0.34 / 0.44	0.31	41.94% (+0.13)	―
Nov 06, 2024	2024 (Q3)	0.30 / 0.35	-0.29	220.69% (+0.64)	―
Aug 07, 2024	2024 (Q2)	0.23 / 0.33	0.33	0.00% (0.00)	―
May 08, 2024	2024 (Q1)	0.20 / 0.19	0.26	-26.92% (-0.07)	―
Feb 28, 2024	2023 (Q4)	0.27 / 0.31	0.22	40.91% (+0.09)	―
Nov 08, 2023	2023 (Q3)	-0.30 / -0.29	0.2	-245.00% (-0.49)	―
Aug 09, 2023	2023 (Q2)	0.25 / 0.33	0.2	65.00% (+0.13)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CPRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$21.79	$19.64	-9.87%
May 07, 2025	$23.46	$22.76	-2.98%
Feb 26, 2025	$20.58	$21.66	+5.25%
Nov 06, 2024	$22.71	$23.25	+2.38%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Catalyst Pharma (CPRX) report earnings?

Catalyst Pharma (CPRX) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Catalyst Pharma (CPRX) earnings time?

Catalyst Pharma (CPRX) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CPRX EPS forecast?

CPRX EPS forecast for the fiscal quarter 2025 (Q3) is 0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing